NCT06671548 2026-02-02
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
Clinical Trials
9 trialsNCT07378098 2026-01-30
to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia
JW Pharmaceutical
Phase 3 Recruiting
NCT04756037 2026-01-08
SERENE
Sumitomo Pharma Switzerland GmbH
Phase 3 Active not recruiting
NCT04655144 2026-01-07
Dex-Fib
University of Miami
Phase 3 Completed
NCT05445167 2025-11-25
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain
Kissei Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT05862272 2025-08-06
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma Switzerland GmbH
Phase 3 Recruiting
NCT03194646 2025-07-28
ASTEROID 6
Bayer
Phase 3 Terminated
NCT05364008 2025-07-25
FRIEND
Yale University
Phase 3 Recruiting
NCT03271489 2025-07-22
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
AbbVie
Phase 3 Completed